As we demonstrate high expression levels of CD70/CD27 in other tumour types using our uniform IHC method, these results underline the potential of anti-CD70 immunotherapy not only in AML, but also in other haematological malignancies and solid tumour types where CD70 is overexpressed. This evidence concerns the gene CD70 and acute myeloid leukemia.